A Randomized, Double Blind, Placebo Controlled, Ascending Single and Multiple Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Food Effect Study of RX-10001 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2014
At a glance
- Drugs RX 10001 (Primary)
- Indications Asthma; Inflammation
- Focus Adverse reactions
- Sponsors Resolvyx Pharmaceuticals
- 03 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2009 Additional lead trial investigator (Renger Tiessen) identified, location (Netherlands) and official title added as reported by ClinicalTrials.gov.
- 18 Jul 2009 Planned end date (Sep 2009) added as reported by ClinicalTrials.gov.